Choose a country to view content specific to your location
Choose a country to view content specific to your location
As regulations tighten, find out how to improve process control through every step of a molecular assay, from samples to results!
DNA genotyping is a powerful technology that allows the identification of genetic variations that can lead to an increased risk of developing certain diseases. Additionally, genotyping has a fundamental role in companion diagnostics, as it enables the characterization of patients’ genetic profiles that can be used to guide treatment decisions.
Here, we will introduce two novel master mixes developed to provide PCR-based identification of mutations directly from the clinical samples, such as blood, plasma or FFPE tissue, bypassing DNA extraction and streamlining the analysis of both liquid and tissue biopsies.
Speakers:
Steve Hawkins, Ph.D., Product Marketing Manager
Join our in-house experts William Ferreira, Ph.D. and Steve Hawkins, Ph.D., for their latest webinar where they share their insights on the newest range of Lyo-Ready Genotyping Direct qPCR Master mixes that support commercial assays designed to detect mutations.
In this presentation, you will learn how to detect single nucleotide polymorphisms (SNPs) directly from blood, plasma, urine, stool or FFPE tissue (down to 1 copy/reaction) using a simplified workflow that eliminates the need for nucleic acid extraction.
Speakers:
William Ferreira, Ph.D., R&D Team Leader
Steve Hawkins, Ph.D., Product Marketing Manager
The recent pandemic and increasing frequency of infectious disease outbreaks due to climate change, urbanization, and increased human migration have drawn significant attention to nucleic acid amplification-based diagnostic technologies (NAAT). Currently, these technologies are mainly accessible only to trained workers in centralized facilities. There is a growing demand for home-based, extraction-free testing using crude samples, however, there are significant challenges in assay development for these point-of-care (POC) applications.
In this upcoming webinar, you will learn:
Speakers:
William Ferreira, Ph.D., R&D Team Leader
Steve Hawkins, Ph.D., Product Marketing Manager
As the IVD industry continues to evolve, new regulations frequently come into place to better control an innovative and growing industry. Molecular IVDs in particular are experiencing tighter regulations regarding the presence of appropriate controls within the assay. All tests must include both positive and negative controls which are subjected to the whole testing process, including the extraction step. Novel co-extracted exogenous controls are providing cutting edge solutions for monitoring RNA or DNA analysis including the detection of potential inhibition. These controls can be used across a variety of sample types and assays, representing a significant advantage over traditional spike-in controls.
Speakers:
Michele Amasio, Ph.D. (Research and Development Senior Manager, Meridian Bioscience)
Moderator:
Steve Hawkins, PhD (Product Marketing Manager, Meridian Bioscience)
qPCR and RT-qPCR are widely used in the development of molecular diagnostic assays with applications in human diagnostics, animal health, environmental, plant and food testing.
Lyophilization is a common technique used for creating ambient temperature stable PCR assays. However, the process is time consuming, complex to optimize and requires expensive equipment. Meridian’s new air-dryable technology replaces lyophilization with a fast, simple, and inexpensive oven-drying process, making it ideal for manufacturing room-temperature stable, highly sensitive and cost-effective molecular diagnostic assays.
This webinar will cover:
Presenters:
Dr Steve Hawkins – Product Marketing Manager
Dr Michele Amasio – Research and Development Manager
Molecular point of care (POC) tests are rapidly gaining traction in the diagnostic market, especially for infectious diseases. While LAMP and qPCR testing share common advantages such as quick turnaround time and high sensitivity and specificity, LAMP has additional benefits, making it possible for testing to be carried out essentially anywhere – from an airport to school, to a remote medical clinic.
In this webinar you will learn about:
Speakers:
Elda Iljazi, Ph.D. – R&D Senior Scientist, Meridian Bioscience
Dr. Michele Amasio – Research and Development Manager
Traditionally, qPCR and RT-qPCR diagnostic assays include DNA/RNA extraction and purification steps to remove inhibitors from the PCR reactions, to meet the assay specificity and sensitivity. However, these steps are laborious, expensive, and time-consuming. To overcome this, Meridian has developed inhibitor tolerant mixes specifically for blood, saliva, urine, and stool. Meridian’s Direct Sample-Specific qPCR Mixes are the first mixes on the market overcoming the limitations of inhibitors inherent in the various clinical specimens, for ultimate assay sensitivity and specificity.
In this webinar our speakers will discuss:
The optimization strategy and methodology that have led to the development of these specimen-specific mixes, which have superior performance compared to other products on the market and enable faster, more sensitive, and cost-effective diagnostic assays.
Speakers:
Dr. Rachel Currier- Acting Team Leader, Research & Development
Dr. Thomas Fouqueau- Acting Team Leader, Research & Development
Moderator
Dr. Steve Hawkins, Product Marketing Manager
Direct qPCR has many advantages over traditional qPCR workflows that involve DNA/RNA extraction. However, achieving high sensitivity with direct qPCR using whole blood samples has been challenging due to the presence of qPCR inhibitors within the sample (such as heme, salts, and proteins), and preservatives or anti-coagulants that are added during the sample collection process. The inhibitors can negatively impact the performance of the enzymes used in qPCR and RT-qPCR and they limit the amount of sample that can be added to the reaction, overall reducing the assay sensitivity and accuracy. In this talk, we will be discussing Meridian’s novel solution to overcome PCR inhibitors in direct qPCR and RT-qPCR, enabling greater sensitivity for direct detection from whole blood, improving assay reproducibility, and reducing assay development time.
Presenters
Thomas Fouqueau, PhD
Acting Team Leader, R&D, Meridian Life Science
Rachel Currier, PhD
Acting Team Leader, R&D, Meridian Life Science
Meridian offers diagnostic manufacturers the complete solution with over 3,000 antigens and antibodies covering more than 500 diseases and an extensive range of specialty qPCR/RT-qPCR master mixes and molecular enzymes all manufactured under ISO13485 regulations.
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our Privacy Statement.
